Oxford Pharmascience Licenses Colonic Drug Delivery Technology

Oxford Pharmascience partners with University of London to have the option to license and research an advanced colonic drug delivery technology.

Drug delivery specialist Oxford Pharmascience has signed a worldwide exclusive option for up to 18 months to license and research an advanced colonic drug delivery technology from The School of Pharmacy, University of London, with a specific intention to develop and commercialise a novel application.

The platform technology developed by Abdul Basit and his research group at the London School of Pharmacy provides for superior controlled delivery of drugs to the colon.

The targeting of drugs to the colon can be utilised as a means to achieving localised therapy for disease states such us irritable bowel syndrome, constipation, diarrhoea, infection and carcinoma, but also as a portal for the entry of drugs into the systemic circulation potentially improving the clinical profile of c